« previous next »
Pages: [1]

Author Topic: Zinbryta (daclizumab) pulled from market due to safety concerns  (Read 285 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9842
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Case of immune-mediated encephalitis related to daclizumab therapy
« on: August 04, 2018, 07:00:52 am »

From PubMed (August 4, 2018). The same issue of Multiple Sclerosis Journal, which is where the article appears, includes an article entitled "Immune-mediated encephalitis with daclizumab: The final nail."  The article below is entitled "A case of immune-mediated encephalitis related to daclizumab therapy."

https://www.ncbi.nlm.nih.gov/pubmed/30073905
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20 - 3/16/24.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
96 Views 		Last post May 31, 2016, 01:48:51 pm
by agate
0 Replies
210 Views 		Last post July 11, 2017, 03:01:11 pm
by agate
0 Replies
37 Views 		Last post May 17, 2021, 09:17:00 pm
by agate
0 Replies
18 Views 		Last post February 19, 2023, 09:43:41 pm
by agate
0 Replies
5 Views 		Last post February 01, 2024, 10:13:30 am
by agate